Clinical Trial Update: Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating darovasertib (IDE196), a PKC inhibitor, in patients with solid tumors harboring GNAQ/GNA11 mutations or PRKC fusions, including met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Cutaneous Melanoma
• Uveal Melanoma

Drugs mentioned

• Darovasertib (darovasertib)

Snippet

Sponsor: IDEAYA Biosciences | Conditions: Metastatic Uveal Melanoma, Cutaneous Melanoma | Phase 1, Phase 2 | Status: RECRUITING